Efalizumab is a humanized monoclonal antibody binding to lymphocyte function-associated antigen (LFA-1). LFA-1 belongs to the family of the |32 integrins and is expressed on the surface of T cells (CD4+ cells, T-help-er cells). It is involved in several T-cell activities, such as T-cell activation and migration, as well as T-cell adhe sion during cellular interactions that are important for induction and maintenance of immune-mediated inflammatory processes. Efalizumab (Raptiva) is indicated for treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to, other systemic therapies including cyclo-sporine, methotrexate and PUVA.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.